Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Journal of Gastroenterology and Hepatology|October 15, 2019
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infectionHidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, et al.
Journal of Viral Hepatitis|July 7, 2019
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in JapanHiroki Ikeda, Tsunamasa Watanabe, Masanori Atsukawa, et al.
Hepatology International|March 5, 2020
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter studyAkito Nozaki, Masanori Atsukawa, Chisa Kondo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2021
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosisMasanori Atsukawa, Akihito Tsubota, Chisa Kondo, et al.
Journal of Gastroenterology and Hepatology|January 18, 2020
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from JapanHidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, et al.
Open Forum Infectious Diseases|May 25, 2019
Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in JapanHidenori Toyoda, Masanori Atsukawa, Haruki Uojima, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 8, 2026
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic RegionsHidenori Toyoda, Yujin Hoshida, Neehar D Parikh, et al.
Infectious Diseases and Therapy|September 8, 2020
Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter StudyMasanori Atsukawa, Akihito Tsubota, Chisa Kondo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2023
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular CarcinomaHidenori Toyoda, Mounika Kanneganti, Jonathan Melendez-Torres, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Pageof 12